Radgocitabine

N/A

Report date: 2026/01/23 20:01:08
NME

Base Information

Drug NameRadgocitabine
Drug Alias NameCNDACTAS-109DFP-10917NS-917
ClassificationSmall molecules > Nucleosides and nucleotide derivtives > Nucleoside analogues
Mechanisms of ActionDNA-directed DNA polymerase inhibitors
TargetsDNA-directed DNA polymerase
Therapy Area/IndicationsColorectal NeoplasmsLeukemia, Myeloid, AcutePrecursor Cell Lymphoblastic Leukemia-Lymphoma
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusDiscontinued (Phase 3 Clinical)
Highest Status in ChinaN/A
Originator CompaniesDelta-Fly Pharma Inc
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesTaiho Pharmaceutical Co LtdDelta-Fly Pharma Inc
Active IndicationsN/A
Inactive IndicationsColorectal NeoplasmsLeukemia, Myeloid, AcutePrecursor Cell Lymphoblastic Leukemia-Lymphoma

Other Information

ATC CodeN/A
Related LinksN/A